FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Fresenius Kabi Sensorcaine-MPF Recall

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200…

Fresenius Kabi USA, LLC · Lake Zurich, IL

Risk level
Class II
Reported by FDA
Jan 25, 2023
Recall ID
D-0129-2023
Check your lot numberHow we source this data

Summary

Fresenius Kabi recalled Sensorcaine-MPF starting Nov 22, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0129-2023 on Jan 25, 2023. Reason: Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product. Status: Terminated.

Why it was recalled

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Product description

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Lot numbers, UPCs & expiration codes

Batch #: 6128800, exp 12/2023

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0129-2023
Classification
Class II
Status
Terminated
Recall initiated
Nov 22, 2022
FDA report date
Jan 25, 2023
Quantity
31,600 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Fresenius Kabi USA, LLC

Original FDA data

Every field from FDA enforcement report D-0129-2023, exactly as published.

Show all FDA fields
City
Lake Zurich
State
IL
Status
Terminated
Country
United States
Event ID
91198
Address
3 Corporate Dr
Code information
Batch #: 6128800, exp 12/2023
Postal code
60047-8930
Report date
Jan 25, 2023
Product type
Drugs
Recall number
D-0129-2023
Classification
Class II
Recalling firm
Fresenius Kabi USA, LLC
Product quantity
31,600 vials
Termination date
Oct 23, 2023
Reason for recall
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.
Distribution pattern
Nationwide in the USA
Recall initiation date
Nov 22, 2022
Initial firm notification
Letter
Center classification date
Jan 13, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0129-2023, published Jan 25, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls